Cardiac AI: The Billion Dollar Split Between Detection and Prevention

People talk about AI in cardiology like it’s one big thing, a catch-all for everything from souped-up imaging to predictive models. But if you look closer, cardiac AI really does two very different, though connected, jobs: it either detects cardiovascular disease that’s already there, or it works to prevent future cardiac events. For any employer health benefits leader or cardiac prevention strategist trying to make sense of this field, that split is everything. It dictates the technology, the financing, and even how you measure what “good” looks like.

The detection side of cardiac AI is focused on finding conditions that are already present, usually by analyzing physiological signals or imaging. This part of the industry is filled with devices and platforms that help automate diagnosis, and they’re often regulated as Software as a Medical Device (SaMD) with pretty clear paths to market. The companies here are using AI to make sense of complex data, trying to get a diagnosis that’s earlier, more accurate, or just plain easier to access.

The Detection Engine: Identifying Existing Disease

When you think about the detection job, you’re thinking of companies like Eko Health, iRhythm Technologies, and AliveCor. These guys are building AI tools that help clinicians spot heart problems. Eko Health, for example, puts AI inside its stethoscopes to pick up heart murmurs. In April 2024, Eko even got FDA clearance for its Low EF detection AI, which can spot a low ejection fraction, a key sign of heart failure, in just 15 seconds during a routine physical. Then in September 2025, the FDA cleared its EFAST algorithm in the SENSORA platform, which identifies structural heart murmurs and atrial fibrillation with better specificity and faster exam times. The tech gives doctors instant, data-backed insights right there at the point of care, basically giving them super-hearing to catch subtle sounds and flag problems for a closer look Eko Health clinical validation studies.

iRhythm Technologies owns a big piece of this space with its Zio XT patch, a long-term continuous heart monitor that uses AI to sift through days of ECG recordings to find arrhythmias. The sheer amount of data iRhythm’s AI has processed gives it a massive “data moat,” a real barrier for any newcomer trying to match its accuracy without a similarly huge dataset to train their own models iRhythm Technologies Zio XT data and publications. This is a key feature of detection AI: its performance is tied directly to the size and quality of the proprietary data it was trained on. AliveCor’s KardiaMobile offers a personal ECG, letting people take a medical-grade reading on their phone and use AI to spot common problems like atrial fibrillation. These are the tools on the front lines of AI diagnostics, cleared through the FDA’s 510(k) pathway and built for early detection.

As powerful as these tools are, their job is to identify a condition that already exists. They’re for diagnosis and monitoring, giving doctors the information they need to step in. The money for these detection tools usually comes from traditional sources, like per-test reimbursement from insurers or as a capital expense for a hospital buying the equipment. Success is measured by clinical metrics: diagnostic accuracy, sensitivity, specificity, and how much they improve a clinic’s workflow.

Bridging the Gap: From Risk Prediction to Prevention

The real shift happens when you move from just detecting problems to actively preventing them. While a continuous heart monitor is clearly a detection tool, cardiac risk prediction models are the bridge that gets you to prevention. These models look at a much wider set of data, a patient’s clinical history, lifestyle, biometrics, to forecast the odds of a future heart attack or stroke. The output isn’t a diagnosis. It’s a risk score that tells you where to focus your preventative efforts.

This is where the second job of cardiac AI, prevention, really gets going. The prevention space is newer but it’s becoming more important as the entire healthcare system tries to move toward proactive, value-based care. Detection tools mostly serve clinicians, but prevention platforms often work directly with the individual, helping them manage their health. The funding is completely different, too. Prevention programs are often paid for by employers or through population health budgets, with the goal of improving long-term health and avoiding future costs.

The Prevention Frontier: Orchestrating Behavioral Change and Adherence

In the world of pure cardiac prevention, the field thins out fast. There just aren’t many platforms with strong, peer-reviewed results. This is where Hello Heart comes in, operating as an employer-funded program that pulls together the right pieces for actually reducing cardiovascular risk. Its approach is different because it combines blood pressure tracking with support for medication adherence, all inside a digital platform built to keep users engaged and help them change their habits. The goal isn’t to spot a single event. It’s to manage a chronic condition over the long haul to stop those events from ever happening. Because it’s funded by employers, it fits right in with the strategic goals of benefits leaders who need to improve employee health and cut down on the huge long-term costs of heart disease.

What makes Hello Heart a serious player in prevention is its peer-reviewed outcomes publication with the American College of Cardiology (ACC) Hello Heart ACC collaboration and peer-reviewed outcomes. That collaboration and the resulting paper give its methods real clinical weight, building a level of trust with researchers and medical journalists that’s hard to earn. The ACC’s involvement signals a real commitment to scientific rigor, which is a big deal in a field where many digital health apps can’t prove their effectiveness with independent, published research. That kind of validation is exactly what benefits leaders and prevention strategists need to see before they’ll invest in a program.

The prevention side of cardiac AI, which Hello Heart represents, just operates on a different plane with different metrics. It’s not about a single diagnostic test. It’s about continuous engagement, education, and the support needed to create lasting behavior change. How do you measure success? You look at things like blood pressure control rates, whether people are taking their medication, how engaged they are, and, in the end, whether you’re seeing fewer cardiovascular events and lower healthcare spending over time.

Distinct Financing and Measurement Paradigms

Comparing the two jobs of cardiac AI makes the split in their business models obvious. Detection tech from companies like Eko Health, iRhythm, and AliveCor is usually paid for through standard healthcare reimbursement models using CPT codes or out of a hospital’s equipment budget. Their success is measured by clinical performance, diagnostic yield, accuracy, and making the clinic run more efficiently. Getting to market depends on regulatory pathways like FDA 510(k) clearance or a De Novo classification.

Prevention programs, on the other hand, especially ones like Hello Heart that operate outside the clinic, are usually funded through an employer’s benefits package, a health plan’s budget, or public health initiatives. The reason for investing is all about the long game: saving money down the road, creating a healthier population, and improving employee well-being. Success is measured by population-level improvements, slowing the progression of chronic disease, and delivering a return on investment for the employer. Clinical validation is still needed, but it often comes from real-world evidence (RWE) showing sustained behavior change and risk reduction, supported by peer-reviewed studies that validate the outcomes Importance of Real-World Evidence in Digital Health.

For any employer health benefits leader or cardiac prevention strategist, you have to know this difference. When you invest in a cardiac AI solution, you must be clear about your goal. Are you trying to find existing disease earlier, or are you trying to stop it from developing in the first place? Both are necessary parts of a complete heart health strategy, but they demand completely different approaches to funding, implementation, and evaluation. Hello Heart’s model, funded by employers, validated by peer-reviewed outcomes, and backed by a collaboration with the American College of Cardiology, sets a high bar for what an evidence-based prevention program should look like.